Stock ACW ACTINOGEN MEDICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:53 2024-05-31 am EDT 		5-day change 1st Jan Change
0.029 AUD -.--% Intraday chart for Actinogen Medical Limited +7.41% +31.82%
May. 30 Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer MT
May. 15 Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7% MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 11.19 24.56 215.9 89.78 72.65 73.28 -
Enterprise Value (EV) 1 3.556 19.91 215.9 73.58 64.19 73.28 73.28
P/E ratio -1.13 x -4.65 x -47.1 x -9.23 x -6.76 x - -
Yield - - - - - - -
Capitalization / Revenue 2.3 x 6.8 x - 24.4 x 13.8 x 9.32 x 9.5 x
EV / Revenue 2.3 x 6.8 x - 24.4 x 13.8 x 9.32 x 9.5 x
EV / EBITDA -1,236,814 x -5,023,224 x - -9,875,267 x -7,113,389 x - -
EV / FCF - - - - -8.32 x -5.43 x -5.59 x
FCF Yield - - - - -12% -18.4% -17.9%
Price to Book - - - - - - -
Nbr of stocks (in thousands) 1,119,231 1,116,231 1,660,559 1,795,644 1,816,252 2,526,921 -
Reference price 2 0.0100 0.0220 0.1300 0.0500 0.0400 0.0290 0.0290
Announcement Date 8/16/19 8/26/20 8/30/21 8/25/22 8/30/23 - -
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Net sales 1 4.863 3.61 - 3.681 5.255 7.863 7.716
EBITDA -9.049 -4.889 - -9.092 -10.21 - -
EBIT -9.403 -5.302 - -9.492 -10.62 - -
Operating Margin -193.36% -146.84% - -257.86% -202.08% - -
Earnings before Tax (EBT) -9.888 -5.331 - -9.497 -10.75 - -
Net income -9.888 -5.331 -3.915 -9.497 -10.75 - -
Net margin -203.33% -147.64% - -258% -204.63% - -
EPS -0.008880 -0.004730 -0.002760 -0.005420 -0.005920 - -
Free Cash Flow 1 - - - - -8.735 -13.49 -13.12
FCF margin - - - - -166.23% -171.6% -170.01%
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 8/16/19 8/26/20 8/30/21 8/25/22 8/30/23 - -
1AUD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2023 S1
Net sales 1 1.14
EBITDA -
EBIT 1 -7.345
Operating Margin -644.28%
Earnings before Tax (EBT) -
Net income 1 -7.439
Net margin -652.51%
EPS -
Dividend per Share -
Announcement Date 2/22/23
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 7.64 4.65 - 16.2 8.46 - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - - - - -8.73 -13.5 -13.1
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - 0.02 - 0 0.04 0.18 0.72
Capex / Sales - 0.63% - 0.08% 0.7% 2.23% 9.36%
Announcement Date 8/16/19 8/26/20 8/30/21 8/25/22 8/30/23 - -
1AUD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACTINOGEN MEDICAL LIMITED Stock Actinogen Medical Limited
+31.82% 48.66M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACW Stock
  4. Financials Actinogen Medical Limited